Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349913 | 0.89 | CYP2D6 (0.49) | CYP2D6MAPTSMN1; SMN2RAB9AGLA | |
| SCHEMBL13097106 | 0.89 | MAOB (0.41) | CYP2D6MAOBMAPTSMN1; SMN2RAB9A | |
| SCHEMBL13097261 | 0.89 | CYP2D6 (0.43) | CYP2D6MAPTSMN1; SMN2TDP1HTT | |
| SCHEMBL13096970 | 0.87 | MAOB (0.51) | MAOBMAPTSMN1; SMN2RAB9AGLA | |
| SCHEMBL13097181 | 0.86 | MAOB (0.40) | CYP2D6MAOBMAPTTDP1 | |
| SCHEMBL13096824 | 0.85 | CYP2D6 (0.49) | CYP2D6MAOBMAPTSMN1; SMN2RAB9A | |
| SCHEMBL13096808 | 0.85 | GPBAR1 (0.51) | CYP2D6MAOBMAPTSMN1; SMN2KMT2A | |
| SCHEMBL13097311 | 0.83 | MAOB (0.39) | CYP2D6MAOBMAPTSMN1; SMN2RAB9A | |
| SCHEMBL13097298 | 0.83 | CYP2D6 (0.38) | CYP2D6MAOBMAPT | |
| SCHEMBL13096805 | 0.83 | APP (0.45) | MAOBMAPTSMN1; SMN2RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885MAOB 200/4885MAPT 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.